Accueil   Diary - News   All news Biom’up sees a strong commercial uptake in HEMOBLASTTM Bellows in the US and Europe

Biom’up sees a strong commercial uptake in HEMOBLASTTM Bellows in the US and Europe

 

Biom’up (the “Company”), a specialist in surgical hemostasis, announces today an update on its first months of commercialization of HEMOBLAST Bellows in the US and Europe and confirms a strong uptake among hospitals and surgeons.


Since its introduction to the US market in July 2018, 26 hospitals have purchased HEMOBLAST Bellows, indicating that the product has already successfully passed hospital evaluations. In total, more than 240 US hospitals are now also currently evaluating HEMOBLAST Bellows, up from 140 in mid-September.

 

Read the press release